ICCM IceCure Medical Ltd.

Nasdaq icecure-medical.com


$ 0.72 $ 0.01 (2 %)    

Tuesday, 18-Nov-2025 15:57:03 EST
QQQ $ 598.79 $ 0.00 (0 %)
DIA $ 461.92 $ 0.00 (0 %)
SPY $ 662.50 $ 0.00 (0 %)
TLT $ 88.97 $ 0.00 (0 %)
GLD $ 378.19 $ 0.00 (0 %)
$ 0.7228
$ 0.71
$ 0.72 x 1,000
$ 0.78 x 468
-- - --
$ 0.52 - $ 1.55
508,069
na
nm
$ 1.85
nm
TBD
na
na ($ 0.10)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 icecure-medical-receives-registration-approval-for-its-prosense-system-for-distribution-by-swissmedic

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minim...

 icecure-medical-receives-nasdaq-delisting-notification-co-given-time-till-may-11-2026-to-regain-compliance

IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destr...

 icecure-medical-promotes-shay-levav-to-coo-as-company-expands-commercial-activities-in-us-following-fda-marketing-clearance-for-prosense

Mr. Levav's appointment ensures seamless and focused organizational structure as Company expands commercial activities in t...

 hc-wainwright--co-maintains-buy-on-icecure-medical-raises-price-target-to-25

HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical (NASDAQ:ICCM) with a Buy and raises the price target from ...

 fda-grants-marketing-authorization-to-icecures-de-novo-application-for-prosense-cryoablation-system-for-local-treatment-of-breast-cancer

ProSense® is the first and only medical device to be granted FDA marketing authorization for the local treatment of breast canc...

 icecure-showcases-cryoablation-advances-at-eusobi-2025-full-capacity-workshop-5-prosense-abstracts-presented-and-grant-award-for-imaging-biomarker-study

IceCure's exclusive workshop was filled to capacity – Unlocking De-Escalation of Care: Cryoablation for Breast Cancer led b...

 icecure-showcases-prosense-cryoablation-with-key-studies-and-training-at-the-cardiovascular-and-interventional-radiology-society-of-europe-annual-meeting-on-september-13-17-2025

Presentations from 5 Key Opinion Leaders on ProSense® cryoablation including 3 independent studies on breast cancer and 1 on en...

 icecure-medicals-prosense-cryoablation-shows-high-patient-satisfaction-and-best-ablation-rates-in-studies-published-in-european-journal-of-surgical-oncology-and-radiology

Article published in European Journal of Surgical Oncology focused on cosmetic outcomes and patient satisfaction reports 95% of...

 icecure-medical-files-for-mixed-shelf-offering-of-up-to-100m

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION